^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

temuterkib (LY3214996)

i
Company:
Eli Lilly
Drug class:
ERK2 inhibitor, ERK1 inhibitor
Phase 1
OHSU Knight Cancer Institute
Recruiting
Last update posted :
02/13/2025
Initiation :
08/01/2019
Primary completion :
06/01/2026
Completion :
02/01/2028
UGT1A1 • CD4
|
UGT1A1*1*1
|
Lynparza (olaparib) • Cotellic (cobimetinib) • Imjudo (tremelimumab-actl) • onvansertib (PCM-075) • azenosertib (ZN-c3) • saruparib (AZD5305) • temuterkib (LY3214996)
Phase 1/2
Eli Lilly and Company
Recruiting
Last update posted :
01/28/2025
Initiation :
07/19/2021
Primary completion :
06/01/2026
Completion :
06/01/2026
KRAS
|
KRAS mutation • KRAS G12C • KRAS G12
|
Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • erlotinib • carboplatin • Tyvyt (sintilimab) • Verzenio (abemaciclib) • pemetrexed • batoprotafib (TNO155) • temuterkib (LY3214996) • LY3295668 • olomorasib (LY3537982)
Phase 1/2
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
05/30/2024
Initiation :
12/02/2020
Primary completion :
12/31/2025
Completion :
12/31/2025
KRAS • BRAF • MAP2K1
|
Erbitux (cetuximab) • Verzenio (abemaciclib) • temuterkib (LY3214996) • Datalai (cetuximab biosimilar)
Phase 1
Nader Sanai
Recruiting
Last update posted :
03/27/2024
Initiation :
07/08/2020
Primary completion :
12/01/2024
Completion :
02/01/2025
CDKN2A • CDK4 • CDKN2B
|
CDK4 amplification
|
Verzenio (abemaciclib) • temuterkib (LY3214996)
Phase 1
Eli Lilly and Company
Completed
Last update posted :
11/22/2022
Initiation :
09/29/2016
Primary completion :
02/10/2021
Completion :
10/24/2022
BRAF • NRAS
|
BRAF V600E • NRAS mutation • BRAF V600 • RAS mutation
|
Erbitux (cetuximab) • gemcitabine • Verzenio (abemaciclib) • albumin-bound paclitaxel • Braftovi (encorafenib) • temuterkib (LY3214996) • midazolam hydrochloride
Phase 1
The Netherlands Cancer Institute
Recruiting
Last update posted :
06/03/2022
Initiation :
03/31/2022
Primary completion :
01/31/2024
Completion :
07/01/2024
EGFR • KRAS • PIK3CA • MET • PTEN • HRAS
|
vociprotafib (RMC-4630) • temuterkib (LY3214996)
Phase 1
Dana-Farber Cancer Institute
Withdrawn
Last update posted :
02/05/2020
Initiation :
02/03/2020
Primary completion :
02/03/2020
Completion :
02/03/2020
PLCG2
|
Imbruvica (ibrutinib) • temuterkib (LY3214996)